Objective To investigate the expression and clinical significance of miR-21 and miR-155 in the molecular subtypes of invasive breast cancer.Methods The clinicopathologic data of 91 cases of invasive breast cancer were retrieved.The expression levels of miR-21 and miR-155 were detected by qRT-PCR.Results The relative expression levels of miR-21 in luminal A-like,luminal B-like,HER2,and TNBC (triple-negative breast cancer) subtypes of breast cancer were 0.000±2.238,1.008±1.297,1.670±1.774 and 0.983±1.630,respectively,and the relative expression levels of miR-155 were -2.313±1.077,-1.022±1.511,-0.051±0.903 and -0.728±1.585,respectively.There were significant differences in the relative expression levels of miR-155 of luminal B-like,HER2,and TNBC subtypes versus that in luminal A-like subtype (P<0.001).Conclusion Detecting the expression levels of miR-155 in invasive breast cancer may be a new approach for guiding breast cancer patients of luminal type to undertake chemotherapy or not.
XU Ming
,
XIE Yiqun
,
ZHU Jiahui
,
HUANG Bin
. Value of miR-155 and miR-21 in diagnosis of molecular subtypes of breast cancer[J]. Surgical Research and New Technique, 2017
, 6(4)
: 229
-234
.
DOI: 10.3969/j.issn.2095-378X.2017.04.001
[1] Goldhirsch A,Wood WC,Coates AS,et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol,2011,22(8):1736-1747.
[2] Coates AS,Winer EP,Goldhirsch A,et al.Tailoring therapies-improving the management of early breast cancer:St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015[J].Ann Oncol,2015,26(8):1533-1546.
[3] Yoruker EE,Aydogˇan F,Gezer U,et al.Analysis of circulating microRNAs during adjuvant chemotherapy in patients with luminal A breast cancer[J].Mol Clin Oncol,2015,3(4):954-958.
[4] Gwak JM,Kim HJ,Kim EJ,et al.MicroRNA-9 is associated with epithelial-mesenchymal transition,breast cancer stem cell phenotype,and tumor progression in breast cancer[J].Breast Cancer Res Treat,2014,147(1):39-49.
[5] Lakhani SR,Ellis IO,Schnitt SJ,et al.WHO classification of tumours of the breast[M].4th ed.Lyon:International Agency for Research on Cancer,2012:13-31.
[6] Goldhirsch A,Winer EP,Coates AS,et al.Personalizing the treatment of women with early breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J].Ann Oncol,2013,24(9):2206-2223.
[7] Lee JA,Lee HY,Lee ES,et al.Prognostic implications of microRNA-21 overexpression in invasive ductal carcinomas of the breast[J].J Breast Cancer,2011,14(4):269-275.
[8] Chen J,Wang BC,Tang JH.Clinical significance of microRNA-155 expression in human breast cancer[J].J Surg Oncol,2012,106(3):260-266.
[9] 傅少梅,张宏伟,刘默芳,等.MiR-155和miR-21在乳腺癌组织中的表达[J].中华实验外科杂志,2011,28 (8):1240.
[10] Liu J,Mao Q,Liu Y,et al.Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients[J].Chin J Cancer Res,2013,25(1):46-54.
[11] Nina P,Radoslav D,Vladan B,et al.MicroRNA in breast cancer:the association with BRCA1/2[J].Cancer Biomark,2017,19(2):119-128.
[12] Chang S,Wang RH, Akagi K,et al.Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155[J].Nat Med,2011,17(10):1275-1282.
[13] Kong W,He L,Richards EJ,et al.Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer[J].Oncogene,2014,33(6):679-689.
